The underlying mechanisms are associated with the C/EBPα-S193A mutation preventing the interaction of C/EBPα with p300, blocking the activation of genes involved in the development of fatty liver, fibrosis, and increased liver proliferation. The gene discussed is CEBPA; the disease is Hepatic steatosis.